Literature DB >> 16709799

Monocyte/macrophage dysfunctions do not impair the promotion of myelofibrosis by high levels of thrombopoietin.

Orianne Wagner-Ballon1, Hédia Chagraoui, Eric Prina, Micheline Tulliez, Geneviève Milon, Hana Raslova, Jean-Luc Villeval, William Vainchenker, Stéphane Giraudier.   

Abstract

Several lines of evidence indicate that the megakaryocyte/platelet lineage is crucial in myelofibrosis induction. The demonstration that NOD/SCID mice with functionally deficient monocytes do not develop fibrotic changes when exposed to thrombopoietin (TPO) also suggests an important role for monocyte/macrophages. However, in this animal model, the development of myelofibrosis is dependent on the level of TPO. This study was conducted to investigate whether NOD/SCID mice exposed to high TPO levels mediated by a retroviral vector would be refractory to the development of bone marrow fibrosis. We show that TPO and TGF-beta1 in plasma from NOD/SCID and SCID mice engrafted with TPO-overexpressing hemopoietic cells reach levels similar to the ones reached in immunocompetent mice, and all animals develop a myeloproliferative disease associated with a dense myelofibrosis at 8 wk posttransplantation. Monocytes in NOD/SCID mice are functionally deficient to secrete cytokines such as IL-1alpha in response to stimuli, even under TPO expression. Surprisingly, the plasma of these mice displays high levels of IL-alpha, which was demonstrated to originate from platelets. Together, these data suggest that completely functional monocytes are not required to develop myelofibrosis and that platelets are able, under TPO stimulation, to synthesize inflammatory cytokines, which may be involved in the pathogenesis of myelofibrosis and osteosclerosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16709799     DOI: 10.4049/jimmunol.176.11.6425

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.

Authors:  Lilian Varricchio; Annalisa Mancini; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2009-06-01       Impact factor: 2.929

Review 2.  The chronic myeloproliferative disorders and mutation of JAK2: Dameshek's 54 year old speculation comes of age.

Authors:  Kenneth Kaushansky
Journal:  Best Pract Res Clin Haematol       Date:  2007-03       Impact factor: 3.020

3.  Cooperative effect of the attenuation determinants derived from poliovirus sabin 1 strain is essential for attenuation of enterovirus 71 in the NOD/SCID mouse infection model.

Authors:  Minetaro Arita; Yasushi Ami; Takaji Wakita; Hiroyuki Shimizu
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

Review 4.  Megakaryocyte Contribution to Bone Marrow Fibrosis: many Arrows in the Quiver.

Authors:  Alessandro Malara; Vittorio Abbonante; Maria Zingariello; Annarita Migliaccio; Alessandra Balduini
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-11-01       Impact factor: 2.576

Review 5.  Focus on Osteosclerotic Progression in Primary Myelofibrosis.

Authors:  Mariarita Spampinato; Cesarina Giallongo; Alessandra Romano; Lucia Longhitano; Enrico La Spina; Roberto Avola; Grazia Scandura; Ilaria Dulcamare; Vincenzo Bramanti; Michelino Di Rosa; Nunzio Vicario; Rosalba Parenti; Giovanni Li Volti; Daniele Tibullo; Giuseppe A Palumbo
Journal:  Biomolecules       Date:  2021-01-19

Review 6.  Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.

Authors:  Daniel Arthur Corpuz Fisher; Jared Scott Fowles; Amy Zhou; Stephen Tracy Oh
Journal:  Front Immunol       Date:  2021-06-01       Impact factor: 8.786

Review 7.  Recent advances in understanding myelofibrosis and essential thrombocythemia.

Authors:  William Vainchenker; Stefan N Constantinescu; Isabelle Plo
Journal:  F1000Res       Date:  2016-04-19

8.  Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm.

Authors:  David C A Molitor; Peter Boor; Andreas Buness; Rebekka K Schneider; Lino L Teichmann; Ruth-Miriam Körber; Gabor L Horvath; Steffen Koschmieder; Ines Gütgemann
Journal:  Ann Hematol       Date:  2020-10-26       Impact factor: 3.673

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.